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ABSTRACT Inspired by recent suggestions that the Alzheimer’s amyloid b peptide (Ab) can insert into cell membranes and
form harmful ion channels, we model insertion of the 40- and 42-residue forms of the peptide into cell membranes using a Monte
Carlo code which is speciﬁc at the amino acid level. We examine insertion of the regular Ab peptide as well as mutants causing
familial Alzheimer’s disease, and ﬁnd that all but one of the mutants change the insertion behavior by causing the peptide to
spend more simulation steps in only one leaﬂet of the bilayer. We also ﬁnd that Ab42, because of the extra hydrophobic
residues relative to Ab40, is more likely to adopt this conformation than Ab40 in both wild-type and mutant forms. We argue
qualitatively why these effects happen. Here, we present our results and develop the hypothesis that this partial insertion
increases the probability of harmful channel formation. This hypothesis can partly explain why these mutations are neurotoxic
simply due to peptide insertion behavior. We further apply this model to various artiﬁcial Abmutants which have been examined
experimentally, and offer testable experimental predictions contrasting the roles of aggregation and insertion with regard to
toxicity of Ab mutants. These can be used through further experiments to test our hypothesis.
INTRODUCTION
Scientiﬁc and public interest in Alzheimer’s disease has
surged in the last several decades. The reason for this is
simple: with increasing life expectancy, Alzheimer’s disease
has emerged as the most prevalent form of late-life mental
failure in humans (Selkoe, 2001).
Alzheimer’s disease (AD) is a neurodegenerative disease
involving progressive memory impairment, altered behavior,
decline in language function, disordered cognitive function,
eventual decline in motor function, and, ﬁnally, death
(Selkoe, 2001). In AD, the brain is typically marked by le-
sions (Selkoe, 2001), neuronal damage, and vascular damage
(Durell et al., 1994). These lesions are typically associated
with extracellular plaques, called amyloid plaques, and
intraneuronal ﬁbrillar tangles (Durell et al., 1994; Selkoe,
2001). The tangles are composed of a protein called Tau and
are called Tau tangles, whereas the extracellular plaques are
largely composed of amyloid b peptide (Ab) in 40- and 42-
residue forms (Selkoe, 2001) (denoted Ab40 and Ab42,
respectively). These insoluble amyloid plaques composed of
Ab are considered a hallmark of AD. However, they are not
speciﬁc to AD (Dickson and Vickers, 2001) and have been
observed in older patients free from AD symptoms (Jarrett
et al., 1993). It has been pointed out that correlations
between amyloid plaque density and severity of dementia
are weak, whereas there are stronger correlations between
soluble Ab levels and severity of dementia (Walsh et al.,
2002). This is one reason for the suggestion that oligomers of
Ab may be more important to toxicity than large insoluble
aggregates or plaques. Evidence for this idea has been
provided in vivo (Walsh et al., 2002) and in vitro (Hartley
et al., 1999; Lambert et al., 1998).
One mechanism by which oligomers can damage cells is
formation of pores or ion channels through the cell
membrane. Early work in this area showed that Ab can
insert into planar lipid bilayers and allow a calcium current
upon insertion, and further that these channels can be
blocked (Arispe et al., 1993), suggesting that the calcium
current is really due to channel formation, not just bilayer
permeabilization by the peptide. Theoretical modeling based
on predicted secondary structures for membrane-bound Ab
has suggested that the Ab peptide can form channels with
four or six Ab subunits in each leaﬂet of the bilayer (for
a total of 8 or 12 per channel; Durell et al., 1994). More
recent work has been done using atomic force microscopy to
look at the structure of Ab inserted in planar lipid bilayers
and has found what appear to be channels consisting of four
or six visible subunits around a central pore, consistent with
the theoretical picture described above. The monomers
oligomerize after insertion into the bilayer. Furthermore, in
the presence of these oligomers, current can ﬂow (Lin et al.,
2001). Lin et al. (2001) also show that, under similar
conditions, Ab42 induces neuritic degeneration and death in
cell culture and that this toxicity is calcium-dependent and
blocked by zinc. Imaging work by another group has also
shown that Ab40 oligomers with the E22G mutation (where
glutamate, E, at residue 22 is replaced with glycine, G),
which causes a form of familial AD, can form pore-like
structures (Lashuel et al., 2002). These pore-like structures
actually could be intermediates which, when not membrane-
bound, build up into the amyloid plaques observed in the
brain of AD patients (Lashuel et al., 2002).
Based on these suggestions, and the observation of Lin
et al. (2001) that oligomers in the membrane form after
insertion of monomers, we model insertion of the Ab peptide
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into the cell membrane. We ﬁrst examine the regular Ab40
and Ab42 peptides, then the 40- and 42-residue versions of
all of the mutations in the Ab peptide that are known to cause
familial AD (FAD) and reduce the average age of onset for
the disease compared to people with sporadic AD (Selkoe,
2001). We believe FAD mutants provide a tool for assessing
proposed toxicity mechanisms, in that the biological toxicity
mechanism should explain why these mutants cause FAD.
Our reasoning in looking at these mutants is that if the
insertion behavior of the FAD mutant peptides is different,
this could make a difference in the prevalence of oligomers
in the membrane and thus have an effect on toxicity, if
membrane-associated oligomers are indeed important for
toxicity in vivo. Although some earlier modeling work has
dealt with the structure of Ab40 in a lipid bilayer (Pellegrini-
Calace et al., 2003), we believe this work is the ﬁrst to
compare insertion of FAD mutants.
This system is modeled using a Monte Carlo (MC) code
which has been developed to study insertion behavior of
peptides into lipid bilayers. This model, which is speciﬁc at
the amino acid level, allows us to simulate larger peptides
and longer timescales than traditional molecular dynamics
simulation studies. The conﬁgurational steps are sufﬁciently
small that it has been used successfully to suggest insertion
mechanisms, as well as to describe insertion conformations
for some peptides (Maddox and Longo, 2002a,b). Here, we
ﬁnd that in all cases the peptide inserts relatively easily.
However, we ﬁnd differences in the conformations the
peptide adopts once inserted. These differences in the
prevalence of conformations are our central result. Relative
to the normal Ab peptide, most of the FAD mutant peptides
are more likely to insert only partially in the bilayer. We
point out similarities between this partially inserted confor-
mation and the predicted channel structures (Durell et al.,
1994). Thus we suggest that FAD mutants may, in this way,
facilitate formation of harmful channels. Moreover, the
Ab42 peptide, with additional hydrophobic residues, has
a greater tendency than Ab40 to hang up in this confor-
mation, and this may correlate with the increased toxicity
of Ab42.
INTRODUCTION TO THE MODEL AND METHOD
Model energy function
The Monte Carlo model used here has been described in detail in an earlier
publication in this journal (Maddox and Longo, 2002a). Accordingly, we
give a brief overview of the essentials here and direct the interested reader to
the earlier reference for greater detail.
The model follows previous work from the past decade, most notably and
closely that of Milik and Skolnick (1992, 1993) and Baumgaertner (1996).
Each amino acid residue is treated as a sphere of identical 1.5 A˚ radius.
There are three contributions to the potential energy function which are
residue-independent: 1), Us, which is a hard-core steric interaction prevent-
ing residue-residue overlap; 2), UT, an energy measuring the cost of rotating
the peptide planes of successive residues, which is periodic in the torsional
angle f between successive residues and has a shallow minimum at f ¼
52.1; and 3), UA, characterizing the energy of distortion of the angle u
between adjacent bonds, with a shallow minimum at u ¼ 89.5.
The lipid bilayer with surrounding water is modeled as a medium without
molecular speciﬁcity, but with three different spatial regions. The bilayer’s
normal is taken to lie along the z axis, so these regions are invariant in the
x–y plane. The bilayer has overall thickness 2(z01 zh), where z0 is the length
of the acyl chains of a given leaﬂet, and zh is the width of the headgroup
region. We have used zh ¼ 4.5 A˚ and z0 ¼ 13.5 A˚. We have also tried
different chain lengths z0 but we do not present the results here as they were
not signiﬁcantly different except for reductions in the amount of the
transbilayer conformation of the inserted peptide when the membrane is
sufﬁciently thick, as we discuss in Results.
The water-lipid medium is characterized by three dimensionless
functions, two of which couple linearly to residue speciﬁc parameters we
discuss in the next paragraph. These functions are (as shown in Fig. 1):
1. w(z), which measures the fractional water content; this is modeled as
a step function with exponentially rounded edges (decay length of 2 A˚)
that is zero in the hydrophobic acyl chains, one in the water region, and
varies smoothly through the head region.
2. A polarity function p(z), also exponentially rounded with the same
decay length, and chosen to be one in the lipid head regions and water
while falling to some small value 1–fq (where fq, the polarity factor,
determines the polarity of the tail region, with larger fq corresponding to
a less polar tail region) after approximately one residue diameter into the
tail region.
3. A hydrophobicity function y(z), which is the sum of two exponentially
rounded step functions: one which is zero in the water region and
saturates in the head region, proportional to the total gain of hy-
drophobic energy in the head region, and a second which saturates in
the tail region after approximately one residue diameter and accounts for
the hydrophobic energy gained for residues penetrating the acyl tail
region.The water content w(z) couples linearly to the external hydrogen
bonding energy of each residue, which is residue independent in form.
The net hydrogen bonding energy is taken as UH given by a sum over
residues i as
UH ¼ +
i
ðwðziÞH01 ð1 wðziÞÞHintðiÞÞ; (1)
FIGURE 1 Functions characterizing bilayer properties. The lipid bilayer
is described by three functions, w(z) for the fractional water content, p(z) for
the polarity, and y(z) for the hydrophobicity. Here the z axis is perpendicular
to the plane of the bilayer, and the functions (and the bilayer) are symmetric
at ;z ¼ 0.
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where H0 ¼  6.12 kcal/mol is the transfer energy of an unbonded peptide
group to water and Hint(i) the internal hydrogen bonding energy associated
with a-helix formation given by
HintðiÞ ¼ H0
4
+
n¼4;3;3;4
VHðjr~n1 i  r~ijÞ: (2)
VH is a nearly hard-core function of the separation between residue i and the
potential helical hydrogen bonding partners along the peptide chain, as
proposed by Milik and Skolnick (1993).
Residue speciﬁcity is included in two energies associated with polarity
and hydrophobicity. First, a potential energy term UQ ¼ +iq0ðiÞpðziÞ is
included, where q0(i) is the residue-speciﬁc polar energy associated with
charged or partially charged functional groups. Second, a hydrophobic
energy UB ¼ +iBðiÞ is included, where
BðiÞ ¼ yðziÞb0ðiÞ1 ð1 yðziÞÞb1ðiÞ
4
3 +
n¼4;3;3;4
VHðjr~n1 i  r~ijÞ: (3)
Here, b0(i) is residue-speciﬁc and measures the water-to-alkane Gibbs
hydrophobic transfer energy for residue i, and b1(i) is the maximum
reduction in hydrophobic energy due to helical folding. The value b0(i) is
taken to be proportional to the stochastic accessible area of the residue. The
helical-folding related term derives from the loss of accessible surface area
associated with helix formation. Values for q0(i), b0(i), and b1(i) for all
residues are tabulated in the previous work (Maddox and Longo, 2002a).
Note that because the model treats the lipids and water only as media, the
hydrophobic energy must be included explicitly in our model energy
function.
Because of the way the hydrophobic and hydrogen bonding energies are
calculated—simply based on local helicity—the simulation is biased toward
a-helices, as b-structure involves longer range interactions and is not taken
into account by the model. Therefore, the model will not accurately describe
insertion behavior of any peptide that inserts while in a conformation rich in
b-structure. Fortunately, the monomeric Ab peptide is predicted, based on
secondary structure, to be a-helical between residues 15 and 40 or 42 (Durell
et al., 1994; Pellegrini-Calace et al., 2003) when membrane-bound.
Experimental NMR work in aqueous sodium dodecyl sulfate micelles,
which to some extent resemble a water-membrane medium, conﬁrms this for
Ab40 (Coles et al, 1998). Thus the model’s bias away from b-structure
should not play a signiﬁcant role here. Indeed, we ﬁnd that the region
mentioned above inserts into the membrane in a largely helical structure, as
described below.
Our total energy is then taken as the sum U ¼ US 1 UT 1 UA 1 UB 1
UQ 1 UH. All of our modeling presented below is done at pH 7.0 with
temperature 305 K, and uses a polarity factor fq ¼ 0.85, corresponding to
a polarity between that of octanol and hexadecane. The choice of this value
is based on experimental studies (Grifﬁth et al., 1974; Roseman, 1988) and
earlier simulation work (Maddox and Longo, 2002a).
Monte Carlo simulation details
The simulation method is the canonical MC method. We use periodic
boundary conditions in all three directions, and in the case where the peptide
runs across the boundary, interactions are calculated using the minimum
separation between the two residues in question (the minimum image
convention). New peptide conformations are generated using three different
sorts of moves:
1. Peptide translation: The whole peptide is randomly translated a small
distance (between 0 and 0.2 A˚) along each Cartesian axis.
2. Spike move (two sorts): (a), For an end residue, the virtual bond
connecting it to the chain is rotated slightly, ﬁrst in the x–y plane, and
then in the y–z plane. The angle of rotation is random, between 0 and
20. (b), For a central residue, the residue is rotated a random (between
0 and 20) amount around an axis joining the centers of its nearest
neighbors, while keeping all virtual bond lengths ﬁxed.
3. Slide move: A random virtual bond is selected and all residues on one
side (selected randomly, either up or down the chain) of it are moved
a small, random amount (between 0 and 0.2 A˚), while remaining ﬁxed
relative to one another. The move leaves the initial virtual bond the
same length but rotated relative to the residues it connects.
One MC step consists of one modiﬁcation of each type 1, 2, and 3, where the
choice of residue is random for moves 2 and 3. Modiﬁcations are accepted or
rejected with a probability given by the usual Boltzmann factor p ¼ eDURT so
that favorable moves, with a negative DU, are always accepted, and some
unfavorable moves are accepted.
In our work, we wanted to capture insertion behavior without biasing
results by initial peptide conformations. We have done two groups of
simulations to accomplish this. First, we have started the peptide outside the
bilayer in the aqueous phase in a random conformation. Second, we have
started the peptide in an initially helical, fully inserted conformation.
MC simulations can be used to investigate nonequilibrium properties
(e.g., insertion mechanisms) or equilibrium properties (e.g., inserted
conformations) of a system. When these simulations are used to study
equilibrium properties, it is important to ensure that the system has fully
equilibrated before data collection begins. If this is not done carefully, one
consequence is that the so-called equilibrium state might depend on the
initial conditions. To establish an appropriate period of equilibration, we
monitored the average energy of the peptide as a function of simulation
steps. As the peptide equilibrates (reaching its energetically preferred
conformation(s)), the average energy decreases from an initially higher
value. Thus we can get a reasonable idea how many simulation steps it takes
for this to happen simply by plotting energy versus step number.
Using this method, we ﬁnd that for insertion from an initial conformation
outside the bilayer, a 30-million-step equilibration period is usually
sufﬁcient, whereas for an initially inserted and helical conformation, 30
million steps is always sufﬁcient. Although both initial conformations
eventually produce the same equilibrated state, the inserted helical con-
formation converges more rapidly and is used, with an equilibration period
of 50 million steps, in all our simulations (unless otherwise noted).
As a further test that our equilibration period is sufﬁcient, we have also
used conformations from peptides at the end of an entire simulation run as
starting points for new simulations, and the results at the end of both
simulations are within our error bars of one another.
It is worth pointing out that no equilibration would be required if the
insertion mechanism is being studied. However, in this work, we ﬁnd that in
every case insertion is fairly easy, as we discuss in Results. Thus we focus on
peptide conformations at equilibrium.
Data collection
Every MC simulation run employs a unique set of random numbers,
resulting in a slightly different result each trial (similar to the way in which
no two experimental measurements are identical). More accurate data are
therefore generated by averaging multiple runs. Here, we have run
a minimum of 10 trials for every peptide: ﬁve beginning in initially helical
and inserted conformations, and ﬁve with initially random conformations
outside the bilayer. Following equilibration (discussed above), data is
collected for 50 million steps. In this article we report the results of the
initially inserted conformations, thus our results are averaged over
a minimum of ﬁve such trials. However, as we will discuss in the appendix
on data analysis, in some cases we use more trials.
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RESULTS
Overview
Overall, we simply input the sequence of Ab40 and Ab42
and various mutants and run the simulations. As discussed
above, we do multiple trials for each peptide and average the
results. What we ﬁnd, brieﬂy, is that the peptides all insert
relatively easily into the bilayer if they begin initially outside
the bilayer, and we do not ﬁnd that the FAD mutations
signiﬁcantly effect this ease of insertion. However, we ﬁnd
that the mutations do inﬂuence the conformation the peptide
adopts once inserted into the bilayer. Therefore, our focus in
this work is not on details of how the peptide inserts, though
we believe it is likely that insertion proceeds via one of the
two main insertion mechanisms described previously
(Baumgaertner, 1996; Maddox and Longo, 2002a).
One of our fundamental results is that the peptide appears to
exhibit multiple possible inserted conformations which have
nearly the same energies, thus allowing the peptide to switch
between conformations often in the course of a simulation.
We have previously described such behavior as conforma-
tional partitioning (Maddox and Longo, 2002b). We ﬁnd that
that the Ab peptide and its mutants can always adopt the same
small set of conformations. However, the mutations alter the
number of MC steps the peptide spends in each of these
conformations (which, in a real system, would correspond to
the number of inserted peptides in each conformation). These
conformations are shown in Figs. 2 and 3.
Essentially, it is quite easy to distinguish three conforma-
tions: the ﬁrst has the last several residues anchored in the
lower head region. We call this conformation transbilayer.
The second conformation is similar, but usually much more
prevalent since the last residues are hydrophobic and prefer
to remain in the tail region. This is especially true in the case
of Ab42. In this conformation, the essential difference is that
the tail of the peptide is not anchored and thus is fairly ﬂoppy
and able to change the angle it makes with the z axis easily.
We call this conformation fully inserted. The third con-
formation is different in that in the ﬁrst two, only residues
1–15 or so remain in the upper lipid head region, while in the
third conformation, the polar residues 22–23 and/or 26–28
also remain in the upper head region (along with some of
their neighbors), where there is still some water content. As
a result, the C-terminus (residue 40 or 42) does not stick
down into the lipid tail region nearly as far as in the other two
conformations. We call this conformation partially inserted.
In this case all, or almost all, of the peptide is only in the
upper leaﬂet of the bilayer.
This third, partially inserted conformation can be divided
into two conformations simply by distinguishing whether it
is residues 22–23 that remain in the upper head region, or
residues 26–28. This separation of conformations is shown
in Fig. 3. Some of our analysis is done grouping these
together, and some by separating them, as we will discuss
below.
Brieﬂy, we ﬁnd that when the FAD mutations have an
effect on the insertion behavior, it is usually by causing the
mutant peptides to favor the partially inserted conformation
more than wild-type. The E22G mutant is an exception, as it
essentially eliminates this conformation. We refer the reader
to the Appendix for detailed discussion of our data analysis
procedure. Overall, however, the basic output of the
simulation is the number of steps, or percentage of steps,
each residue in the peptide spends at each z-coordinate. We
can plot this for all residues (Fig. 4) or particular residues
(Figs. 5–7). With some analysis of these (the data analysis is
explained in the Appendix) we are able to get accurate
measurements of increases or decreases in the number of
steps the peptide spends in a given conformation, relative to
wild-type. We are able to do this whether we choose to
separate the peptide’s conformations into three or four
groups. Results obtained using these methods are presented
in Table 1 and Table 2.
FIGURE 2 Primary inserted conformations of the Ab peptide. We ﬁnd
that in every case, the inserted peptides can adopt essentially three different
conformations. Mutations appear to alter the percentage of steps the peptide
spends in each conformation but do not fundamentally change the
conformations. (a) Transbilayer. The peptide inserts with the last several
residues near the C-terminus in the lower lipid head region; the portion
crossing the bilayer is roughly helical. (b) Fully inserted. Just like a, except
the last several residues are not anchored in the lower head region, meaning
that the conformation is fairly ﬂexible. (c) Partially inserted. Like b, except
now much more of the peptide is tethered to the upper head region by the
polar residues 22–23 and 26–28, whereas before only residues 1–15 or so
were in the upper head region. The conformations shown are for Ab40, but
Ab42 has similar conformations with two additional residues (isoleucine
and alanine) at the C-terminus.
FIGURE 3 Subconﬁgurations associated with locations of the polar
residues. We can further break up the partially inserted conformation, from
Fig. 2 c, into two conformations: (a) a conformation where only residues 22–
23 remain in the upper head region, and (b) a conformation where both
residues 22–23 and 26–28 remain in the upper head region.
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Normal Ab peptide insertion
As detailed in the Appendix, some results for Ab40, Ab42,
and various mutants, are shown in Figs. 5–7. We have also
extracted the number of steps in each conformation and
present these (measured as percentages of total steps) in
Table 1, along with standard deviations. As we discuss in the
Appendix, the percentages for conformations (b) and (c) are
not completely accurate as absolute measures of the number
of steps in those conformations, but the change relative to
wild-type is accurate.
It is important to note that there is a fundamental
difference between Ab40 and Ab42. While both can adopt
all the conformations of Fig. 2, Ab42 spends many fewer
steps in conformation (a). This is because the last two
residues of Ab42 add signiﬁcantly to the hydrophobicity of
the C-terminus (see sequence in Fig. 4), as both are nonpolar
and isoleucine is strongly hydrophobic. One might well ask,
however, why Ab40 has its last three residues in the lower
head region at all, especially the ﬁnal two valines, which are
nonpolar and strongly hydrophobic. To understand this
effect, it is worth noting that in this conformation, the
transbilayer helix begins after, or around, residue 16, lysine,
which is the ﬁnal charged and polar residue before a number
of nonpolar, hydrophobic residues, beginning with leucine.
To remove residues 39 and 40 from the lower head region
would require either the peptide to insert at a more shallow
angle so that these residues do not make contact with the
lower head region, or putting a kink in the helix (as in Fig. 2
b) so that they do not make contact. In the ﬁrst case,
changing the insertion angle would move lysine, and
possibly residues after it (it is immediately followed by
valine), into the upper head region where there is still some
water. This would be costly energetically. So is putting a kink
into the helix. Thus we believe that, in the case of Ab40, the
energy cost of either putting a kink in the helix, or imbedding
K16 and V17 in the upper head region, is comparable to the
energy cost of imbedding V39 and V40 in the lower head
region, thus the conformation in Fig. 2 a does occasionally
happen. On the other hand, for Ab42, the additional I41
makes this conformation so costly that it almost never
happens. This reduction in the transmembrane conformation
results in an increase in the prevalence of the other two
conformations relative to Ab40 which, if correct, could help
explain why Ab42 is typically more toxic.
It is probably important to point out that our results
do not necessarily mean Ab40 would be biologically
FIGURE 4 Number of steps at each z-coordinate (vertical axis is z axis;
darker means more steps) plotted versus residue number (sequence shown),
from 1–40 for Ab40, a, and from 1–42 for Ab42, b. Note that on residue 30,
there appear three dark regions, corresponding to three peaks, whereas
residues 26 and 28, for example, have four peaks. This result is important for
our data analysis. Note also that the transbilayer conformation for Ab42 is
less common than for Ab40 (compare the darkness, or number of steps, of
the lowest peak on residue 40 for Ab40 and Ab42). The sequence of Ab
has polar residues shaded, hydrophobic residues underlined, and charged
residues with charges indicated.
FIGURE 5 Binned numbers of steps spent at each z-coordinate for residue
40 of (a) Ab40 and (b) Ab42. Each plot also shows various FAD mutations.
It is easily apparent that Ab42 spends signiﬁcantly fewer steps in the fully
inserted conformation (leftmost peak) compared to Ab40. It is difﬁcult to tell
much about the other conformations by looking at this distribution for
residue 40, but the prevalence of these can be extracted from other residues.
Note that the lipid head regions are from z ¼ 13.5 A˚ to z ¼ 18 A˚ (and
similarly for negative z).
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transmembrane. We have tried making the bilayer slightly
thicker (by 5 A˚) and the transbilayer conformation essen-
tially disappears. This means the transmembrane insertion is
due to the limited space between head regions, as we argued
above. Biologically, the membrane could be slightly thicker
than our model, or the peptide might cause a small bulge in
the membrane to accommodate a fully inserted, rather than
transbilayer, conformation. So, although the simulation does
produce this transbilayer conformation, we have no reason
to believe that this conformation would be distinct from
the fully inserted conformation in biological systems. On the
other hand, this conformations does exist in our model. Here,
it is the reduction in the prevalence of this conformations that
makes the other two conformations more prevalent for
Ab42 than Ab40.
FAD Ab peptide insertion
FAD mutations
There are a number of known FAD mutations, including
some involving Ab (as well as others involved in other
aspects of the disease including Ab production). These are
named by the populations they were ﬁrst found in and include
Flemish (A21G), Arctic (E22G), and Iowa (D23N) (Mur-
akami et al., 2002). Murakami et al. also include Dutch
(E22Q) and Italian (E22K) but there is some dispute about
whether these are properly to be considered AD mutations
(Melchor et al., 2000; Nilsberth et al., 2001; Wattendorff
et al., 1995). To understand this, it is important to note that
AD is often accompanied by cerebral amyloid angiopathy
FIGURE 6 Binned number of steps spent at each z-coordinate for (a)
residue 30 of Ab40 and (b) residue 35 of Ab42. These are the residues we
picked which best distinguish three groups of conformations. The leftmost
group on both, which is very small for Ab42, is in conformations that appear
nearly transbilayer. The middle group is in conformations that are inserted
and fairly ﬂoppy, as in Fig. 2 b, and the rightmost group is in the partially
inserted conformation. It can be clearly seen that for Ab40, all of the
mutations but E22G and A21G result in an increase in this last peak relative
to wild-type, and for Ab42 all of them except E22G do, as well.
FIGURE 7 Binned number of steps spent at each z-coordinate for residue
26 of (a) Ab40 and (b) Ab42. For this residue, there are four apparent peaks,
corresponding to the conformations of Fig. 2, a and b, and Fig. 3. For Ab42,
the transbilayer conformation is so small that there is no apparent peak. For
Ab40, it is the leftmost peak, followed by the fully inserted peak, then the
partially inserted peaks: the peak of Fig. 3 a, and then the peak of Fig. 3 b.
Notice that for both Ab40 and Ab42, the FAD mutants increase the weight
of the rightmost conformations (those of Fig. 3) relative to wild-type, except
for the E22G mutant.
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(CAA), deposition of Ab in blood vessels of the brain
potentially leading to vessel rupture and stroke, especially in
FAD cases (Murakami et al., 2002). Wattendorff et al. (1995)
point out that classic Alzheimer’s plaques are rarely found in
the Dutch CAA case and dementia and death are due to
cerebral hemorrhage involving damage to blood vessels, as is
also the case in the Italian E22K mutant (Melchor et al.,
2000). But the fact that AD also involves amyloid angiopathy
leaves open the possibility that the Dutch and Italian forms
are vascular forms of AD (Wattendorff et al., 1995).
Here, we set aside the issue of whether or not the Dutch
and Italian Ab mutations are actually AD mutations or
whether they should be regarded as something different and
simply model insertion of these peptides into cell mem-
branes. It is known that even the Dutch E22Q and Italian
E22K mutant peptides interact with cell surfaces of cerebral
vascular smooth muscle cells and cause cell death in vitro
(Melchor et al., 2000). Thus, it is conceivable that the
mechanism may be similar to that described by Lin et al.
(2001) and the type of cells being damaged may simply be
different—either cerebral vascular smooth muscle cells
(Melchor et al., 2000) or brain pericytes (Verbeek et al.,
1997) rather than neurons. For simplicity, we will call all of
these FAD mutations.
It is also important to note that these Ab mutations are
autosomal-dominant (Nilsberth et al., 2001) and, in addition
to lowering the age of onset for AD compared to sporadic
cases, cause AD in all subjects with the mutations who live
long enough. Many of these mutations also lead to increased
Ab levels, but that cannot be the sole cause, as at least the
Arctic mutation (Lashuel et al., 2002) leads to decreased
levels. The cause of disease also cannot be simply the
increased propensity to form ﬁbrils or aggregates, because at
least the Flemish mutation does not increase ﬁbril formation
(Murakami et al., 2002).
FAD mutation results
Results for these mutations are shown in Figs. 5–7, and
presented in reduced form in Table 1. We ﬁnd that the most
consistent difference in results relative to wild-type, for both
Ab40 and Ab42, is that four of the ﬁve FAD mutants
increase the number of steps the peptide is in a conformation
like that of Fig. 2 c. The E22G mutant, however, results in
a huge decrease of this conformation.
To understand our results, consider the changes in polarity
and hydrophobicity the mutations involve. The polarity and
hydrophobicity values used in this model have been tabulated
before (Maddox and Longo, 2002a) and will not be repeated
here, but it is worthwhile to discuss the mutations brieﬂy. The
A21G mutant involves a decrease in hydrophobicity, hence
should cause residue 21 to more strongly prefer to be in the
upper head region and thus result in an increase in the
prevalence of the partially inserted conformation (Fig. 2 c).
This is what we ﬁnd, at least for Ab42 (for Ab40, the
percentage stays about the same). The E22Q mutant involves
a fairly large increase in polarity and slight increase in
hydrophobicity, thus the polarity should dominate and cause
TABLE 1 Frequency of each conformation for native and FAD Ab peptides
Peptide form Onset % Trans.
Three-peak analysis Four-peak analysis
% Fully ins. % Partially ins. D% Upper(a) D% Upper(b)
WT Ab40 72.8 15.6 6 3.8 48 6 5.2 36.3 6 6.8 — —
Ab42 2.1 6 0.5 58.5 6 5.6 39.4 6 5.8 — —
A21G Ab40 52 17.6 6 3.0 48.3 6 6.8 34.1 6 8.0 0.5 6 1.8 2.9 6 8.4
Ab42 1.9 6 0.7 44.4 6 5.4 53.7 6 5.4 2.8 6 3.2 14.8 6 6.9
E22G Ab40 57 27.4 6 7.5 67.4 6 7.0 5.13 6 7.0 11.8 6 1.6 13.2 6 6.2
Ab42 2.3 6 1.7 94.8 6 7.0 1.29 6 1.0 16.8 6 3.7 9.6 6 5.6
E22Q Ab40 ? 13.6 6 4.6 43.6 6 5.5 42.8 6 5.5 6.4 6 3.5 2.8 6 11.0
Ab42 2.0 6 0.3 55.8 6 6.9 42.2 6 7.0 4.5 6 3.4 1.8 6 8.7
E22K Ab40 ? 15.5 6 9.6 37.9 6 5.2 46.6 6 6.0 9.9 6 2.3 2.2 6 10.0
Ab42 1.3 6 0.8 34.2 6 10.5 64.5 6 9.4 9.4 6 8.0 14.6 6 17.1
D22N Ab40 69 13.1 6 9.2 30.0 6 8.8 56.8 6 10.2 8.6 6 7.2 10.8 6 16.2
Ab42 1.2 6 0.5 41.1 6 16.3 57.7 6 16.7 0.6 6 5.8 16.0 6 11.4
Ages of onset (where known) (Grabowski et al., 2001; Li et al., 2002; Nilsberth et al., 2001; Roks et al., 2000) and simulation results: percentage transbilayer,
percentages in the fully inserted (Fig. 2 b) and partially inserted (Fig. 2 c) conformations as calculated from the three-peak analysis on residue 30. The last
two columns measure the change in percentage of the conformations of Fig. 3, a and b, relative to wild-type (from the four-peak analysis). For each mutation,
one row represents Ab40 and the next Ab42. Onset age is not speciﬁc to the 40- or 42-residue forms. Here, the only consistent trend that we ﬁnd is that most
of the FAD mutants, with the exception of E22G, appear to increase the percentage of the partially inserted conformation relative to wild-type. This appears
to be true for both Ab40 and Ab42. By way of comparison, the FAD mutations increase ﬁbrillar aggregation of Ab42 in vitro in every case except the A21G
mutant (Murakami et al., 2002) and increase soluble Ab levels in every case but the E22G mutant (Lashuel et al., 2002; Nilsberth et al., 2001). To improve
statistics, wild-type Ab40 results are the average of 25 trials rather than the usual 5; wt Ab42 are the average of 20; A21G Ab40 20 trials; A21G Ab42 10
trials, and Ab42 E22Q and D23N 10 trials each. All the rest are ﬁve trials, as described in Appendix: Data Analysis.
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residue 22 to strongly prefer the upper head region, as we ﬁnd.
The E22Kmutant is quite similar, but involves an even larger
increase in polarity, and should also cause residue 22 to prefer
the upper head region, as we ﬁnd. And the D23N mutant
involves a similar increase in polarity and slight increase in
hydrophobicity, so again the polarity should dominate and
increase this conformation, as we ﬁnd. On the other hand, the
E22Gmutant replaces a polar, charged residue with a neutral,
nonpolar residue and thus residue 22 is now mostly indif-
ferent. This results in the observed huge decrease in the par-
tially inserted conformation.
On one hand, the different behavior of the E22G mutant
could be taken as evidence that there is no consistent change
in insertion behavior, and thus suggest that this may not be
the toxicity mechanism, or at least that oligomerization, not
insertion, is important. That is certainly a possible meaning
of these results. However, we would suggest that the reader
compare the conformation of Fig. 2 c with the channel
structure of Durell et al. (1994), speciﬁcally in Fig. 4 of that
article. Note that there are two helices predicted, from
residues 15–24, running near the upper head region, and
from 25–40 or 25–42, inserted. In Fig. 2 c, we have a nearly
helical region from around residues 14–24 or 25 that is near
the upper head region, and one from 25–40 which hangs
down inserted. Thus it resembles the predicted structure
more than either of the other conformations. In the structure
prediction, the part of the chain before residue 15 folds down
inside the oligomer and forms ab-barrel, which we obviously
do not capture here because we do not have oligomers neces-
sary to stabilize such a structure, and because the model is
not designed to capture b-structure. With the similarity of
Fig. 2 c to the predicted channel structure in mind, we form
the hypothesis that the partially inserted conformations
(Fig. 2 c, or Fig. 3, a and b) are more likely to form channels,
simply because of their resemblance to the structure of the
monomers making up the channels. Below, in the subsection
‘‘Insertion of other mutant Ab peptides’’, we test this
hypothesis against some experimental data for artiﬁcial Ab
mutants, and present predictions for further tests. One might
argue that the observed changes in the prevalence of different
conformations are relatively small and thus would be
unlikely to result in a large difference in the toxicity of the
different mutants. However, these channels consist of eight
or twelve monomers. If one thinks of a large number of
monomers inserted in a bilayer, some will be in each
conformation at any given time, so we can think of the
concentration of each conformation. Consider, then, the
concentration of the conformation that can form channels.
TABLE 2 Frequency of each conformation for artiﬁcial Ab mutants
Peptide form % Trans.
Three-peak analysis Four-peak analysis
% Fully ins. % Partially ins. D% Upper(a) D% Upper(b)
WT Ab40 15.6 6 3.8 48 6 5.2 36.3 6 6.8 — —
Ab42 2.1 6 0.5 58.5 6 5.6 39.4 6 5.8 — —
E22QD23N Ab40 15.5 6 5.0 30.0 6 6.4 54.6 6 6.9 4.4 6 6.3 13.9 6 16.2
Ab42 0.9 6 0.7 24.6 6 11.4 74.4 6 11.4 4.0 6 10.5 30.9 6 19.0
E22A Ab40 23.1 6 7.6 71.7 6 7.1 5.2 6 0.7 10.8 6 2.3 13.3 6 6.3
Ab42 2.0 6 0.4 85.6 6 2.1 12.4 6 2.0 13.8 6 7.0 11.4 6 4.2
E22D Ab40 22.9 6 8.9 64.9 6 7.6 12.2 6 2.0 3.9 6 2.6 13.1 6 6.2
Ab42 1.9 6 1.1 62.9 6 6.6 35.2 6 6.6 5.9 6 3.4 0.4 6 10.7
A2S Ab40 17.6 6 9.1 49.3 6 6.4 33.1 6 5.0 1.2 6 9.9 3.2 6 9.7
Ab42 2.2 6 1.3 60.4 6 3.4 37.4 6 3.3 2.4 6 3.3 5.3 6 8.7
F19S Ab40 1.6 6 2.4 5.3 6 4.4 93.1 6 4.9 4.9 6 10.3 57.9 6 16.1
Ab42 0.1 6 0.1 10.8 6 5.2 89.1 6 5.2 7.8 6 13.6 43.6 6 14.9
I32S Ab40 14.2 6 7.0 34.7 6 8.7 51.1 6 10.7 1.7 6 3.2 17.0 6 12.6
Ab42 1.5 6 0.7 49.5 6 13.9 49.1 6 14.1 1.1 6 4.5 10.2 6 11.5
I32V Ab40 16.0 6 3.9 58.8 6 2.8 25.3 6 1.3 4.4 6 1.6 10.8 6 6.8
Ab42 2.5 6 1.2 63.2 6 2.1 34.4 6 2.0 0.1 6 3.7 5.7 6 5.6
V36E Ab40 83.0 6 13.9 10.6 6 9.3 6.4 6 6.2 12.7 6 3.0 5.3 6 13.3
Ab42 16.7 6 11.9 36.2 6 19.5 47.1 6 10.5 1.6 6 5.1 5.6 6 11.8
H6R Ab40 17.3 6 4.8 47.7 6 7.7 35.0 6 8.4 2.2 6 2.5 1.2 6 8.8
Ab42 2.0 6 0.6 52.9 6 8.2 45.1 6 8.4 1.8 6 3.7 2.5 6 7.3
Shown are results for artiﬁcial Abmutants mentioned in the literature: percentage transbilayer, percentages in the fully inserted (Fig. 2 b) and partially inserted
(Fig. 2 c) conformations as calculated from the three-peak analysis on residue 30. The last two columnsmeasure the change in percentage of the conformations of
Fig. 3, a and b, relative to wild-type (from the four-peak analysis). The Ab40 E22QD23N mutant is more toxic to HCSM cells than either mutant alone (Van
Nostrand et al., 2001), whereas the E22Dmutant of Ab40 is not toxic to HCSM cells and the E22Amutant is (Melchor et al., 2000). The A2S, F19S, I32V, I32S,
andV36Emutants are known to reduce aggregationofAb42 (Wurth et al., 2002), and theH6Rmutant has been suggested as anFADmutant (Janssen et al., 2003).
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The time it takes for 12 monomers within a bilayer to ﬁnd
each other, or the probability, should scale as c12, where c is
this concentration. Thus a small difference in the amount in
the proper conformation could make a big difference in the
likelihood of forming channels.
Insertion of other mutant Ab peptides
A variety of other data is available on mutant Ab peptides.
Some reduce aggregation in vitro (Wurth et al., 2002), some
might cause FAD (Janssen et al., 2003), and some have
various effects on cultured cerebrovascular smooth muscle
cells (Melchor et al., 2000; Van Nostrand et al., 2001). Here,
we examine some of the mutations which have been men-
tioned in the literature as a test of our hypothesis—if it is
right, and toxicity depends in part on the relative prevalence
of the partially inserted conformation, our results ought to
correlate with the experimental toxicity measurements.
First, we address the E22Q,D23N Ab40 double mutant
created by Van Nostrand et al. (2001). This mutation’s effect
has been examined on human cerebrovascular smoothmuscle
cells (HCSM cells) because the E22Q mutation causes
especially pronounced cerebral amyloid angiopathy and
patients with this mutation typically die of hemorrhage, as
discussed above. HCSM cells are known to degenerate in
CAA in a manner that is associated with Ab deposition
(Melchor et al., 2000). Van Nostrand et al. (2001) found that
the E22Q,D23N double mutant is even more toxic to HCSM
cells than E22Q or D23N alone. Our idea was that the
mechanism for this toxicity also involves insertion of the
peptide and formation of channels, so we modeled this
mutant as well. Results for this mutant are shown in Table 2;
we ﬁnd that the prevalence of the partially inserted con-
formation does increase relative to wild-type. Relative to
the D23Nmutant, which we would predict would be the more
toxic of the E22Q and D23Nmutants, we observe an increase
in the partially inserted conformation only for Ab42. Again,
however, we would argue simply based on the residue
properties that since both the E22Q and D23N mutants
increase preference of those residues for the upper head
region, the double mutant should have a stronger effect on
this than either alone, and thus we expect that, given better
statistics, wewould agree with VanNostrand et al. (2001) and
predict that the double mutant is more toxic than either alone.
Melchor et al. (2000) have found that an artiﬁcial E22D
mutant of Ab40 does not effect HCSM cells, in contrast to
biological E22Q and E22K mutants. They also observed that
the Ab40 E22Amutant is toxic to HCSM cells. Therefore we
model insertion of E22D and ﬁnd (Table 2) that the E22D
mutant results in a decrease in the partially inserted con-
formation (as one would expect due to the decrease in polar-
ity), especially for Ab40. The E22A mutant results in a large
decrease in the partially inserted conformation for both
Ab40 and Ab42 (again, as one would expect due to the de-
crease in polarity). Thus, based on our hypothesis, we would
agree that the E22D Ab40 mutant would not be toxic, but
disagree that the E22A mutant would be toxic. This could be
taken as evidence against our hypothesis or evidence that the
toxicity mechanism is different for HCSM cells.
Janssen et al. (2003) recently identiﬁed a previously
unknown mutation in the Ab peptide in two early-onset AD
patients in the same family. This mutation, H6R, produced
ages of onset ;55. We have here tried this mutation (results
in Table 2) and ﬁnd that it produces insertion behavior that is
within error bars of wild-type. Given the position of the
mutation, this is what we would expect, as it is within the
range of amino acids (1–14 or more) that are ﬁrmly anchored
in or near the upper head region, where there is some water
content. Replacing histidine with arginine, which is even
more polar, does not have a strong effect on this as both try to
remain where there is water, i.e., the surface of the upper
head region. Thus, if toxicity depends only on insertion
conformation, we would suggest that this is indeed not a FAD
mutation. Thus we would suggest testing toxicity of this
mutant in cell culture, particularly as already done for Ab42
by Lin et al. (2001).
Some in vitro work has been done to ﬁnd artiﬁcial mutants
that can reduce aggregation of Ab42 (Wurth et al., 2002).
Unfortunately, this has not yet been extended to include
Ab40. However, we selected some of the point mutations
which are known to reduce aggregation of Ab42 and
modeled the insertion of these. We tried A2S, F19S, I32V,
I32S, and V36E. Results are shown in Table 2. We ﬁnd that
F19S and I32S strongly increase the prevalence of the
partially inserted conformation for both Ab40 and Ab42.
For F19S, this is due to the substitution of polar serine for
strongly hydrophobic phenylalanine, causing residue 29 to
prefer the upper head region; for I32S, the reason is similar.
In this case, the conformation is actually different from
normal in that residue 32 also sticks in the upper head region.
In contrast, the I32V mutant does not result in a large change
relative to wild-type, consistent with the relatively small
change between isoleucine and valine. Unsurprisingly, the
A2S mutant makes no change to insertion behavior (residue
2 is ﬁrmly in the upper head region, so changing it to polar
makes little difference). The V36E mutant, however, as one
might expect, drastically increases the number of steps that
the peptide is transbilayer, as the polar and charged glutamic
acid strongly prefers to be in an environment with more
water. Thus it decreases the prevalence of the partially
inserted and fully inserted conformations. Thus we would
predict that, if our hypothesis is correct, F19S and I32S
should be the most toxic, I32V and A2S should be com-
parable to wild-type, and V36E might be much less toxic
than wild-type. We say might because this probably depends
on the thickness of the bilayer; if the bilayer is too thick it
will probably behave just like wild-type since the E36 could
not reach the lower head region. Thus a testable experimental
prediction of our hypothesis is that toxicity of these mutants
would be related to their insertion behavior as just described.
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We can make a second prediction which is simply based
on the observed insertion behavior of Ab42. Looking at the
insertion behavior of the Ab42 versions of the Wurth et al.
(2000) mutants, we ﬁnd that I32V, A2S, and possibly V36E
insert more like natural Ab42, whereas F19S, I32S, and
possibly V36E insert differently. The reduction in aggre-
gation splits the group differently—I32S aggregates most,
then A2S, V36E, and F19S are similar to one another
and intermediate, and I32V aggregates least (Wurth et al.,
2002). So if ﬁbrillar aggregation primarily causes toxicity,
experiments looking at toxicity should see the latter group-
ing, whereas if insertion behavior is of much more impor-
tance, toxicity experiments should see the former grouping.
DISCUSSION AND CONCLUSIONS
We have here presented work applying a model of peptide
insertion to Ab, a peptide implicated in Alzheimer’s disease.
Speciﬁcally, we have examined the effect of FAD mutations
on the peptide’s insertion behavior, with the idea that any
successful hypothetical toxicity mechanism should be able to
explain why FAD mutations are toxic. Thus if FAD mutants
do not affect peptide insertion into, or oligomerization
within, membranes, the ion channel toxicity mechanism
proposed previously (Arispe et al., 1993; Durell et al., 1994;
Lin et al., 2001) is probably not relevant biologically.
What we ﬁnd is that the FAD mutations do affect peptide
insertion. Four of these ﬁve mutations involve an increase in
polarity or decrease in hydrophobicity and thus cause the
peptide to prefer (relative to wild-type) a conformation
where those residues are in the upper lipid head region (i.e.,
Fig. 2 c). It is interesting to note that a channel structure
suggested previously (Durell et al. (1994), see Fig. 4) has
these residues laying along the surface of the bilayer. Thus
we ﬁnd that four of the ﬁve FAD mutations increase the
resemblance to this conﬁguration.
Based on this similarity, we develop the hypothesis that
causing the peptide to hang up in the upper leaﬂet (the
partially inserted conformation) facilitates formation of
harmful channels. We test this hypothesis on several artiﬁcial
mutations examined in vitro and ﬁnd that it can explain the
change in toxicity of two and is wrong on a third. As a fur-
ther test of our hypothesis, we can offer some testable
predictions. For example, if the hypothesis is right, we would
suggest that the F19S mutant would increase toxicity of Ab
relative to wild-type. Additionally, there are several
mutations known to reduce aggregation of Ab42 that we
predict would promote the insertion behavior that would
facilitate channel formation. Thus, it would be simple to
distinguish between the channel formation toxicity mecha-
nism and the aggregation toxicity mechanism by looking at
the toxicity of these mutants. Even more evidence could be
provided by replicating the work of Lin et al. (2001) but
using various FAD mutants and looking at how these effect
the abundance of channels. Additional information could
also be gained from theoretical work along the lines of that
by Durell et al. (1994) to see what effect these FAD mutants
would have on channel structures.
Overall, this approach of modeling peptide insertion
provides a simple way of making concrete predictions to
distinguish the proposed mechanism of channel formation
from others. The limitation of this approach, however, is that
we can only look at insertion of single peptides, and not
interaction between these. This is ﬁne if formation of channels
depends on having peptides initially in the correct conforma-
tions, which seems reasonable. However, it is also possible
that interaction between inserted peptides causes them to
adopt conformations appropriate for channel formation. If this
is the case, then insight into channel formation would require
a more sophisticated model that can include interaction
between peptides. Even if this is not the case, including
interaction between peptides will certainly answer the ques-
tion of whether FAD mutants affect channel formation in
a consistent waymuchmore thoroughly thanwe are able to do
here. Therefore, this would be a logical continuation of this
work and is something we hope to do in the future.
Even if our hypothesis proves to be wrong, we have
shown that the FAD mutants affect insertion behavior of the
Ab peptide into lipid bilayers, and provided an understand-
ing as to why the FAD mutants affect insertion in the way
they do.
In conclusion, our work shows that most FAD mutations
have a signiﬁcant effect on the insertion of the Ab peptide in
lipid bilayers in this theoretical model, and this effect can
easily be understood by looking at the change in polarity and
hydrophobicity accompanying the mutations. The effect of
FAD mutations on insertion has not been studied previously,
and may be signiﬁcant. Additionally, we offer a hypothesis
based on promoting channel formation by causing peptides
to insert less fully that can help explain toxicity of Ab FAD
mutants, as well as several artiﬁcial mutants studied in vitro.
While this hypothesis is unproven, it is based on the
observation that these peptides do insert into cell membranes
and form ion channels (Lin et al., 2001), and similarities to
theoretically predicted channel structures (Durell et al.,
1994). We provide testable predictions based on this
hypothesis. It should be simple for experimentalists to
disprove this hypothesis, if it is false, or to offer additional
evidence for it, if they follow the experimental suggestions
we offer above. Additionally, our work suggests the value of
further modeling work to describe the full formation of these
channels, rather than just single-peptide insertion.
APPENDIX: DATA ANALYSIS
The basic output of the simulation is the binned number of steps—essen-
tially the frequency with which each residue is found at each z-coordinate.
This can be plotted across all residues and illustrates, as in Fig. 4, that there
are multiple conformations that the peptide can switch between.
In terms of data analysis, it is more useful to plot z-distributions of
speciﬁc residues which can be used to distinguish between the conforma-
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tions described above. For example, residue 40 has a well-deﬁned peak in
the lower head region that can be used to distinguish the transbilayer con-
formation from the other conformations. A plot of residue 40 z-distributions
for various mutations is shown in Fig. 5.
It is somewhat more difﬁcult to distinguish exactly how many steps the
peptide spends in the fully inserted and partially inserted conformations (Fig.
2, b and c). To understand this, it is important to recognize that each
conformation results in a peak for a given residue. That is, from Fig. 2, one
can easily see that the position of residue 28 has three signiﬁcantly different
locations depending on which conformation the peptide is in. As it turns out,
it also has a fourth, which is not very different from the third, as can be seen
in Fig. 3. Unfortunately, these peaks tend to overlap with each other quite
signiﬁcantly—that is, residue 28 can sometimes have similar locations
whether it is in the partially inserted conformation or the fully inserted
conformation. This means that, to extract the number of steps in a given
conformation from the data, it becomes necessary to ﬁt some function to the
peaks and then calculate the number of steps from that.
To do this, we select residues where the peaks appear to be particularly
well separated. For one, we choose residue 30 (for Ab40), because at that
residue, the peaks corresponding to the two partially inserted conformations
actually overlap—that is, residue 30 has the same average location no matter
whether it is residues 22–23 alone that are stuck in the upper head region,
or 22–23 and 26–28. This means that we can extract the weight of
conformation from Fig. 2 c—the conformation grouping these two
together—by looking at this residue. For Ab42, the two peaks of the
partially inserted conformation do not quite overlap for residue 30, but do for
residue 35, so we do the same analysis, but for residue 35. A plot of the
number of steps at each z-value for these residues is shown in Fig. 6.
To separate the two partially inserted conformations of Fig. 3, we choose
three residues that have four peaks that are the most well-separated (unlike
residue 30 or 35, where these two peaks merge into one). These are residues
26, 28, and 31. Plots of the number of steps at each z-value for different
mutations for one of these residues, residue 26, are shown in Fig. 7.
Our goal was to ﬁnd the number of steps in each conformation. Having
chosen the residues where the peaks are the best separated, it is necessary to
ﬁnd the number of steps under each peak. Since they overlap, we ﬁnd that
the best way to do this is to use the least-squares method to ﬁnd ﬁts to each
peak that best describe the whole function. This is probably best understood
using a concrete example, for which we choose residue 26.
For residue 26, we know there are four peaks, and, as seen in Fig. 7, the
locations of these are fairly clearly visible. To ﬁt these peaks, we begin by
averaging all of our results for the wild-type form of Ab40. We assume that
the peaks are Gaussian. Since the peaks are reasonably well separated, we
assume initially that the center of each Gaussian is at the maximum. Then,
we perform a least-squares ﬁt of the standard deviation and amplitude of
each Gaussian. Particularly, we perform our ﬁt by looping through the peaks
and suggesting changes ﬁrst to the standard deviation and then to the
amplitude. Each time, we try both increasing and decreasing the standard
deviation by a speciﬁed step size, and check whether this improves the
quality of the ﬁt. We then move on to the next peak and do the same thing,
then repeat the process for the amplitude. Then we reduce the step size and
repeat the whole process. We do this until the ﬁt can no longer be improved
by further iterations of the process. Having done all that, we also then try
altering the locations of the centers of the Gaussians slightly to see if it
improves the ﬁt. Having then selected optimal standard deviations and center
locations, we store those, and assume that the shape and location of each
peak will remain the same for other simulations, and that simply the
amplitudes will vary. A sample such ﬁt is shown in Fig. 8. As is apparent
from the ﬁgure, the ﬁt is good. Therefore, we concluded that assuming the
peaks are Gaussian is sufﬁcient, at least to get a reasonable estimate of the
number of steps in each conformation.
Having done this, we are able to then perform a four parameter ﬁt for
every other data set for every Ab40 mutation data set, simply by ﬁtting the
amplitudes while keeping the standard deviations and peak locations ﬁxed.
We have also tried allowing the standard deviations to vary when doing
these subsequent ﬁts but this does not substantially improve the quality of
the ﬁt, and it seems reasonable that the shape of a given peak for a given
residue should be constant.
We apply a similar technique to ﬁtting residues 28 and 31, and residue 30,
but we ﬁt residue 30 using only three peaks, and we do the same for Ab42.
Additionally, using this technique, we are able to calculate standard
deviations for a given peptide or mutant. For example, for the D23N mutant,
where residue 23 is changed from aspartate (D) to asparagine (N), we
perform a ﬁt separately for each of our ﬁve MC runs and calculate the area
under each peak. Then, we average the results over all ﬁve trials and
calculate the standard deviation.
For the four-peak case, it is somewhat difﬁcult to accurately separate the
third and fourth peaks, thus it helps that we are able to separately perform ﬁts
to four peaks on residues 26, 28, and 31. We are thus able to take the
apparent change of steps under each of these three peaks relative to the wild-
type and average over all three residues. This signiﬁcantly reduces our error.
There is one more factor which complicates issues. Going back to our
earlier example of the location of residue 28 in Fig. 2, it appears in very
different positions along the z axis depending on which conformation the
peptide is in. However, it is also possible to have conformations where
residue 28 may, for example, be quite low, like it is in the transbilayer
FIGURE 8 Binned number of steps spent at each z-coordinate for residue
26 of (a) Ab40 and (b) Ab42, along with ﬁts used for data analysis. Shown
here are the data for wild-type, compared to ﬁts of Gaussians, as described in
Appendix: Data Analysis. The Gaussians appear to provide fairly good ﬁts
and thus we use these in this work to calculate the number of steps in each
conformation.
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conformation (Fig. 2 a) but residues 38–40 are not in the lower leaﬂet. This
effect gets worse the further the residue being examined is from residue 40,
and is apparent in Figs. 6 and 7 as the area under the transbilayer peak on
those residues is obviously much larger than the area under the same peak on
residue 40, simply because more conformations look similar to the
transbilayer conformation.
This means that the calculated number of steps under each peak for
residues 26, 28, 30, and 31, while accurate, are not really to be taken as
a measure of how many simulation steps the peptide spends in each of those
conformations. Since the peak shapes remain constant over the different
mutations, however, these do accurately describe the change relative to the
wild-type. That is, an increase in the prevalence of the conformation of Fig. 2
c relative to wild-type for a given mutation is correct, while the absolute
number of steps in that conformation may not be accurate, except for the
conformation of Fig. 2 a, which we can extract accurately from residue 40.
As we discussed above, for many of the peptides we have studied results
are averaged over ﬁve trials. However, for some we have used signiﬁcantly
more trials. Speciﬁcally, for wild-type of Ab40 and Ab42, we used more
trials, as it was particularly important to have a good average for those results
since we compare all of our other results to those. For Ab40 we used 25
trials; for Ab42 we used 20. Additionally, for mutants with particularly
small changes relative to wild-type, or particularly large standard deviations,
we also used more runs. We did 20 trials for A21G Ab40; 10 for A21G
Ab42; and 10 each for Ab42 E22Q and D23N. Of the artiﬁcial mutants, we
did 10 trials for Ab40 and Ab42 of both I32S and H6R.
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